Brief: Vaxart Q3 Net Income USD -17.4 Million
02/11/2023 20:02
Nov 02 (Reuters) - Vaxart Q3 basic EPS USD -0.11. * Q3 pretax profit USD -17.361 million * Q3 operating income USD -17.822 million * Q3 operating expenses USD 19.923 million
Recent news on Vaxart
See all newsBrief: Vaxart Expands Intellectual Property Portfolio With European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Q2 revenue falls on lower government contract income
Brief: Vaxart Q2 Net Income USD -13.494 Million
Brief: Vaxart Enters Cooperation Agreement With Stockholder Group And Announces Board And Corporate Governance Enhancements
Vaxart Q1 revenue more than doubles on government contracts